AR and metastatic neoplasm: Participant are enrolled based on the following criteria: (i) metastatic disease at study entry proven by ≥2 bone lesions on bone scan or by soft tissue disease observed by CT/MRI; (ii) disease progression while receiving any androgen deprivation therapy, androgen biosynthesis inhibitors or second-generation AR inhibitors; (iii) recovery from toxicities related to any prior treatments; and (iv) ongoing androgen deprivation therapy with LHRH agonist/antagonist therapy or history of bilateral orchiectomy (NCT05252364).